These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23594711)

  • 21. Estrogens and Coronary Artery Disease: New Clinical Perspectives.
    Meyer MR; Barton M
    Adv Pharmacol; 2016; 77():307-60. PubMed ID: 27451102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause].
    Scarabin PY; Plu-Bureau G
    Arch Mal Coeur Vaiss; 1993 Feb; 86(2):243-8. PubMed ID: 8363427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women, lipoproteins and cardiovascular disease risk.
    LaRosa JC
    Can J Cardiol; 1990 May; 6 Suppl B():23B-29B. PubMed ID: 2188715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys.
    Adams MR; Williams JK; Clarkson TB; Jayo MJ
    Baillieres Clin Obstet Gynaecol; 1991 Dec; 5(4):915-34. PubMed ID: 1822826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Menopause and risk factors for coronary heart disease.
    Matthews KA; Meilahn E; Kuller LH; Kelsey SF; Caggiula AW; Wing RR
    N Engl J Med; 1989 Sep; 321(10):641-6. PubMed ID: 2488072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future.
    Clarkson TB; Meléndez GC; Appt SE
    Menopause; 2013 Mar; 20(3):342-53. PubMed ID: 23435033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
    Vickers MR; MacLennan AH; Lawton B; Ford D; Martin J; Meredith SK; DeStavola BL; Rose S; Dowell A; Wilkes HC; Darbyshire JH; Meade TW;
    BMJ; 2007 Aug; 335(7613):239. PubMed ID: 17626056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
    Burckhardt P
    Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormone replacement in postmenopausal women with coronary heart disease. Results and clinical consequences from recent studies].
    Schurz RA; Benzer W
    Wien Klin Wochenschr; 1997; 109 Suppl 2():42-5. PubMed ID: 9340923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of oestro-feminal on lipid metabolism in postmenopausal women].
    Bohdanowicz-Pawlak A; Milewicz A; Amałowicz B; Tupikowska G; Bolanowski M
    Wiad Lek; 1992 Sep; 45(17-18):689-92. PubMed ID: 1295257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiovascular risk and hormone replacement therapy in menopause].
    Plu-Bureau G
    Therapie; 1999; 54(3):375-80. PubMed ID: 10500454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.
    Mohandas B; Mehta JL
    Curr Opin Cardiol; 2007 Sep; 22(5):434-42. PubMed ID: 17762545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
    Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM
    N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.
    Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P
    Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of postmenopausal hormone substitution on the lipid profile and coagulation factors in female smokers].
    Tatović-Babić D; Beljić T; Drezgić M; Trpković D; Balint-Perić L; Babić D; Nikolić J
    Srp Arh Celok Lek; 2002; 130(11-12):371-5. PubMed ID: 12751159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carcinoma of the breast and hormone replacement therapy for osteoporosis.
    Crawshaw A
    Int J Clin Pract; 2000 Mar; 54(2):99-103. PubMed ID: 10824364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.